Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.
Approval Alert | Nivolumab/Ipilimumab in Unresectable/Metastatic Hepatocellular Carcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL
2
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma
3
Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer
4
Optimizing the Timing of Genetic Testing in Advanced Ovarian Cancer
5
